Holen Sie sich die Stockscreener-App
15.06
2.66%
0.39
Handel nachbörslich:
15.06
Schlusskurs vom Vortag:
$14.67
Offen:
$15
24-Stunden-Volumen:
4,615
Relative Volume:
0.24
Marktkapitalisierung:
$43.42M
Einnahmen:
$5.02M
Nettoeinkommen (Verlust:
$-18.31M
KGV:
-3.3245
EPS:
-4.53
Netto-Cashflow:
$-23.40M
1W Leistung:
-7.49%
1M Leistung:
-8.95%
6M Leistung:
+10.96%
1J Leistung:
-17.61%
1-Tages-Spanne:
$15.00
$15.16
1-Wochen-Bereich:
$14.49
$16.76
52-Wochen-Spanne:
$12.12
$26.99
Vtv Therapeutics Inc Stock (VTVT) Company Profile
Firmenname
Vtv Therapeutics Inc
Sektor
Branche
Telefon
336-841-0300
Adresse
3980 PREMIER DR, HIGH POINT, NC
Vergleichen Sie VTVT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VTVT
Vtv Therapeutics Inc
|
15.06 | 43.42M | 5.02M | -18.31M | -23.40M | -4.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Vtv Therapeutics Inc Stock (VTVT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2019-05-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-04-10 | Herabstufung | Stifel | Buy → Hold |
| 2018-03-08 | Eingeleitet | ROTH Capital | Buy |
| 2018-02-08 | Eingeleitet | Northland Capital | Outperform |
| 2016-09-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2015-09-04 | Eingeleitet | Canaccord Genuity | Buy |
| 2015-08-24 | Eingeleitet | Piper Jaffray | Overweight |
| 2015-08-24 | Eingeleitet | Stifel | Buy |
Alle ansehen
Vtv Therapeutics Inc Aktie (VTVT) Neueste Nachrichten
vTv Therapeutics Holds 2025 Annual Stockholders Meeting - TipRanks
Transcript : VTv Therapeutics Inc.Special Call - MarketScreener
vTv Therapeutics to Participate in the H.C. Wainwright “HCW@Home” Series - GlobeNewswire
vTv Therapeutics Showcases First-in-Class Type 1 Diabetes Treatment at HC Wainwright | VTVT Stock News - Stock Titan
(VTVT) Trading Signals - news.stocktradersdaily.com
(VTVT) Technical Data - news.stocktradersdaily.com
vTv resumes Phase III oral T1D drug study - The Pharma Letter
vTv Therapeutics appoints new CFO amid Phase 3 trial By Investing.com - Investing.com South Africa
vTv Therapeutics Appoints New CFO Amidst Phase 3 Trial - TipRanks
vTv Therapeutics Appoints Michael Tung, M.D., MBA, As Chief Financial Officer - citybiz
VTv Therapeutics Names Michael Tung as Finance Chief - marketscreener.com
vTv Therapeutics (VTVT) Appoints New CFO | VTVT Stock News - GuruFocus
vTv Therapeutics Appoints Michael Tung, M.D., MBA, to Chief Fina - GuruFocus
VTv Therapeutics Names Michael Tung CFO, Effective Immediately - Nasdaq
vTv Therapeutics appoints new CFO amid Phase 3 trial - Investing.com
vTv Therapeutics Appoints Michael Tung, M.D., MBA, to Chief - GlobeNewswire
vTv Therapeutics Advances First-in-Class Oral Type 1 Diabetes Drug as New CFO Joins - Stock Titan
Vtv Therapeutics Inc. Appoints Michael Tung as Chief Financial Officer, Effective May 19, 2025 - MarketScreener
VTv Therapeutics: Q1 Earnings Snapshot - Bluefield Daily Telegraph
How to Take Advantage of moves in (VTVT) - news.stocktradersdaily.com
vTv Therapeutics Highlights Cadisegliatin’s Potential for Diabetes - TipRanks
VTVT Advances Cadisegliatin Program with Phase 3 Study | VTVT St - GuruFocus
vTv Therapeutics advances type 1 diabetes trial By Investing.com - Investing.com South Africa
vTv Therapeutics Inc Reports Q1 2025 EPS of -$0.77, Beating Estimates; Net Loss at $5.1 Million - GuruFocus
vTv Therapeutics Announces 2025 First Quarter Financial Results and Provides Corporate Update - The Manila Times
vTv Therapeutics Accelerates Timeline for First-Ever Oral Type 1 Diabetes Drug as Phase 3 Trial Advances - Stock Titan
VTV Therapeutics Announces Reinitiation Of Screening In CATT1 Phase 3 Trial - marketscreener.com
vTv Therapeutics advances type 1 diabetes trial - Investing.com Australia
VTv Therapeutics Resumes Cadisegliatin Testing in Type 1 Diabetes - marketscreener.com
vTv Therapeutics (VTVT) Resumes Phase 3 Trial for Diabetes Treat - GuruFocus
vTv Therapeutics Announces Reinitiation of Screening in CATT1 Phase 3 Trial Evaluating Potential First-in-Class Liver-Selective Glucokinase Activator Cadisegliatin for Type 1 Diabetes | VTVT Stock New - GuruFocus
vTv Therapeutics (VTVT) Resumes Phase 3 Trial for Diabetes Treatment | VTVT Stock News - GuruFocus
vTv Therapeutics Announces Reinitiation of CATT1 Phase 3 Trial for Cadisegliatin, Shortens Duration to Expedite Topline Data Expected in 2026 - Nasdaq
vTv Therapeutics Announces Reinitiation of Screening in - GlobeNewswire
vTv Therapeutics Announces Reinitiation of Screening in CATT1 Phase 3 Trial Evaluating Potential First-in-Class Liver-Selective Glucokinase Activator Cadisegliatin for Type 1 Diabetes - Stock Titan
How the (VTVT) price action is used to our Advantage - news.stocktradersdaily.com
vTv Therapeutics Inc expected to post a loss of 81 cents a shareEarnings Preview - TradingView
Geode Capital Management LLC Has $158,000 Holdings in vTv Therapeutics Inc. (NASDAQ:VTVT) - Defense World
vTv Therapeutics (VTVT) to Release Quarterly Earnings on Thursday - Defense World
vTv Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:VTVT - Benzinga
vTv Therapeutics (NASDAQ:VTVT) Coverage Initiated at StockNews.com - Defense World
vTv Therapeutics Appoints Barry Brown as Interim CFO - MSN
vTv Therapeutics (NASDAQ:VTVT) Coverage Initiated at HC Wainwright - Defense World
Q1 Earnings Forecast for VTVT Issued By HC Wainwright - Defense World
HC Wainwright Initiates vTv Therapeutics With Buy Rating, $36 Price Target - MarketScreener
This Couchbase Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
HC Wainwright & Co. Initiates Coverage of vTv Therapeutics (VTVT) with Buy Recommendation - Nasdaq
H.C. Wainwright sets $36 target for vTv Therapeutics stock By Investing.com - Investing.com Canada
Finanzdaten der Vtv Therapeutics Inc-Aktie (VTVT)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.45%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):